Conference on 5th Annual Smoking Cessation

Venue: -

Location: -

Event Date/Time: Jan 27, 2011 End Date/Time: Jan 28, 2011
Report as Spam


Conference on 5th Annual Smoking Cessation
Accelerating innovations and assessing new strategies
27th – 28th January 2011, BSG Conference Centre, London, UK

Key Speakers

Raymond Hreiche, Regional Scientific Advisor, Pfizer
Senior Representative, GSK
Mike Kelly, Public Health Director, National Institute for Health and Clinical Excellence (NICE)
Raafat Fahim, President and CEO, Nabi Biopharmaceuticals
Scott Bryson, Lead Specialist in Pharmaceutical Public Health, NHS
Robert Walton, Professor of Primary Medical Care, Barts and The London School of Medicine and Dentistry
Dave Clark, Campaigns and Policy officer, Action on Smoking and Health (ASH)
Simon Gilbody, Professor of Psychological Medicine and Health Services, University of York

Conference Introduction
27th – 28th January 2011, London, UK

Smoking remains one of the biggest health threats in the world, causing 5.4 million deaths worldwide and 100,000 deaths in the UK each year. With governments and health organisations constantly warning of dangers of smoking, there’s never been more pressure on smokers to quit. Figures suggest that around 50% of quit attempts involve the use of smoking cessation aids, usually in the form of nicotine replacement therapy (NRT), purchased over the counter. Most unaided attempts are often not very successful. There is a growing market for new, safe and more effective smoking cessation therapies. This will see the global smoking cessation products market increase with a CAGR of 5% during the period 2008-2024, with revenues increasing from $3504m in 2008, to $7347m by 2024. Growth will be most noted in the emerging economies of Brazil, Russia, China and India (BRIC). Having hosted four previous successful Smoking Cessation events, We are now preparing for its 5th Annual Smoking Cessation conference. This conference will feature key industry experts who will discuss the latest in anti-smoking therapies, examine the challenges in the smoking cessation market, and review current control policies and preventative measures.

Why you should attend this conference:
• Examine the current market potential for emerging anti-smoking products
• Hear the latest innovations in smoking cessation therapies
• Assess the health benefits of smoking cessation
• Understand the effects of smoking on the human body
• Identify novel therapeutic targets for smoking cessation products
• Review the latest in tobacco prevention and control policies
• Use this opportunity as a platform for future collaborations

Who should attend this conference?
VPs, Directors, Heads and Managers of:
• Smoking Cessation
• Anti-smoking Products
• Tobacco Risk/Control
• Tobacco Research
• Clinical Trials
• Clinical Pharmacology
• Pharmacotherapy
• Drug Delivery
• Research & Development
• Scientific Affairs
• Primary Care
• Respiratory
• Therapeutics
• Drug Addiction
• Health Improvement
• Epidemiology
• Consumer Insights
• Outcomes Research
• Product Development
• Pricing
• Marketing/Sales
• Public Affairs/Branding/Advertising
• Regulatory Affairs

Members of:
• Pharma, Biotech & Healthcare Organisations
• Government - Department of Health, NHS PCTs
• Non-profit Organisations/Associations
• Advertising/Public Relations Bodies
• Hospitals